drugset / Trial / NCT03012646

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

NCT03012646

Phase 2 Withdrawn United Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, single-arm trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with Chronic Obstructive Pulmonary Disease (COPD).

Timeline

Start
2017-04
Primary completion
2019-04
Completion
2019-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified 6 ug Inhaled